Recent Articles
Royalty Pharma Stock Should Be Moving Off Your Watchlist
Royalty Pharma stock has faded after rallying immediately after its IPO. With valuation more reasonable, RPRX has a solid long-term case.
What Happened to Gilead Sciences and Is the Stock Still a Buy?
Gilead stock has been under pressure for a few months, giving investors a great risk/reward setup, especially with its coronavirus treatment.
Stock Ideas, Cryptos, and IPOs – Answers To Your Questions
The S&P 500 went five for five this week. It closed at a new all-time high each day… the first time such a feat has been achieved in years. What does this mean for stocks going forward? That’s the big question, and I answer that and much more in this week’s episode of MoneyLine. We'll also dive into what the Fed's new policy means, and we'll look at a bunch of stocks -- including one that has gone up nearly 6X since March. Is it still a buy? Check out this week's episode to find out!
Why Nvidia Stock Still Has More Upside Left
Nvidia has been on fire, causing many to wonder how far it can go. NVDA stock could extend to $535, but that doesn't mean it will stop there.
Under Armour Is Waking Up Far Too Late
When its rivals were taking a difficult stance for justice, Under Armour was busy being toxic. Now, that decision will come to haunt UA stock.
Join Louis Navellier’s Market 360 — FREE!
Get Louis Navellier’s take on the news and events impacting the market, plus his top stock picks.
